[1]高明珠,王进有,张 涛,等.肾癌组织YAP1/TAZ 蛋白表达与临床病理特征及患者远期生存的相关性研究[J].现代检验医学杂志,2022,37(06):1-6+51.[doi:10.3969/j.issn.1671-7414.2022.06.001]
　GAO Ming-zhu,WANG Jin-you,ZHANG Tao,et al.Study on the Expressions of YAP1/TAZ Proteins in Renal Cell Carcinoma and Its Relationships with Clinicopathology and Long-term Survival of Patients[J].Journal of Modern Laboratory Medicine,2022,37(06):1-6+51.[doi:10.3969/j.issn.1671-7414.2022.06.001]
点击复制

肾癌组织YAP1/TAZ 蛋白表达与临床病理特征及患者远期生存的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年06期
页码:
1-6+51
栏目:
论著
出版日期:
2022-11-15

文章信息/Info

Title:
Study on the Expressions of YAP1/TAZ Proteins in Renal Cell Carcinoma and Its Relationships with Clinicopathology and Long-term Survival of Patients
文章编号:
1671-7414(2022)06-001-07
作者:
高明珠; 王进有; 张 涛; 邵 菲
(安徽医科大学第二附属医院肿瘤科，合肥 230601)
Author(s):
GAO Ming-zhu;  WANG Jin-you;  ZHANG Tao;  SHAO Fei
(Department of Oncology ，the Second Hospital of Anhui Medical University, Hefei 230601, China)
关键词:
肾癌; Yes 相关蛋白1; PDZ 结合域的转录共刺激因子; 远期生存
分类号:
R737.11；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.06.001
文献标志码:
A
摘要:
目的 检测肾癌组织Yes 相关蛋白1(Yes-associated protein 1，YAP1)，PDZ 结合域的转录共刺激因子(transcriptional coactivator with PDZ-binding motif，TAZ)蛋白表达，并探讨其与临床病理特征及患者远期生存的关系。方法 前瞻性选取安徽医科大学第二附属医院2016 年1 月～ 2018 年10 月收治的132 例肾癌患者。根据三年内是否死亡将其分为死亡组(n=20)和生存组(n=108)。采用免疫组织化学二步法检测YAP1，TAZ 蛋白表达，用COX 回归分析探讨患者死亡的危险因素。结果 手术组切缘正常组织YAP1，TAZ 蛋白阳性表达率分别为22.41% 和17.24%，癌组织YAP1，TAZ 蛋白阳性表达率分别为53.45% 和48.28%，对应癌组织高于切缘正常组织(χ2=11.864，12.680，P=0.001，0.000)。穿刺活检癌组织YAP1 和TAZ 蛋白阳性表达率分别为77.14% 和62.86%。临床分期、有副肿瘤综合征、有远处转移、伴下腔静脉癌栓、组织学分级与癌组织YAP1 蛋白阳性表达率均呈正相关(χ2=8.664~21.321，P=0.000~0.003)，与TAZ 蛋白阳性表达率也呈正相关(χ2=6.518~25.529，P=0.000~0.001)；癌组织YAP1，TAZ 蛋白阳性表达与肾癌三年内生存率均呈正相关(χ2=10.273，12.657；P=0.001，0.000)；临床分期III ～ IV 期[ 风险比(hazardratio，HR)=3.550，P=0.016]、有副肿瘤综合征(HR=4.267，P=0.012)、组织学III~IV 级(HR=5.382，P=0.001)、癌组织TAZ 蛋白阳性表达(HR=5.760，P=0.007)、伴下腔静脉癌栓(HR=6.508，P=0.005)、有远处转移(HR=7.330，P=0.003)、癌组织YAP1 蛋白阳性表达(HR=7.877，P=0.001)均是肾癌三年内死亡的危险因素。结论 肾癌组织YAP1 和TAZ 蛋白阳性表达率高，且与临床分期、组织学分级、副肿瘤综合征、远处转移和下腔静脉癌栓有关，上述病理特征与癌组织YAP1 和TAZ 蛋白阳性表达均是患者远期生存的影响因素。
Abstract:
Objective To detect the expression of yes-associated protein 1 (YAP1) and transcriptional coactivator with a PDZbinding motif (TAZ) in renal cell carcinoma and explore their relationship with clinicopathology and long-term survival of patients. Methods 132 patients with renal cancer admitted to the Second Affiliated Hospital of Anhui Medical University from January 2016 to October 2018 were prospectively selected. They were divided into death group (n=20) and survival group (n=108) cording to whether they died within 3 years. Immunohistochemical two-step method was used to detect the expression of YAP1 and TAZ proteins, and COX regression analysis was used to explore the risk factors of death. Results The positive expression rates of YAP1 and TAZ protein in the normal tissues in the operation group were 22.41% and 17.24%, respectively, and those were 53.45% and 48.28% in tumor tissues, and those in tumor tissues were higher than normal tissues (χ2=11.864, 12.680, P=0.001, 0.000). The positive rates of YAP1 and TAZ protein expressions in biopsy cancer tissues were 77.14% and 62.86%, respectively. Clinical stage, paraneoplastic syndrome, distant metastasis, inferior vena cava tumor thrombus, histological grade and YAP1 protein positive expression in cancer tissue were positively correlated with positive expression of YAP1 protein in cancer tissues (χ2=8.664 ～ 21.321, P=0.000 ～ 0.003), which were positively correlated with positive expression of TAZ protein in cancer tissues (χ2=6.518 ～ 25.529, P = 0.000 ～ 0.001). The positive expressions of YAP1 and TAZ proteins in cancer tissues were positively correlated with the 3-year survival rate of renal cell carcinoma (χ2=10.273, 12.657, P=0.001, 0.000). Clinical stage III~IV [hazard ratio (HR) =3.550, P = 0.016], paraneoplastic syndrome (HR=4.267, P= 0.012), histological grade III ～ IV (HR=5.382, P = 0.001), positive expression of TAZ protein in cancer tissues (HR=5.760, P= 0.007), with tumor thrombus in inferior vena cava (HR=6.508, P = 0.005), distant metastasis (HR=7.330, P = 0.003), and positive expression of YAP1 protein in cancer tissues (HR=7.877, P = 0.001) were risk factors for death within 3 years in patients with renal cell carcinoma. Conclusion The positive expression rates of YAP1 and TAZ proteins in renal cell carcinoma were high, which were related to clinical stage, histological grade, paraneoplastic syndrome, distant metastasis and inferior vena-cava tumor thrombus. The above pathological characteristics and positive expressions of YAP1 and TAZ proteins in renal cell carcinoma would be the influencing factors of long-term survival in patients with renal cell carcinoma.

参考文献/References:

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA-A Cancer Journal for Clinicians, 2020, 70(1): 7-30.
[2] 王昱政 , 胡樱 .1992～ 2016年中国肾癌死亡趋势的年龄-时期-队列分析 [J].中华流行病学杂志 , 2021, 42(3):508-512． WANG Yuzheng, HU Ying. Age-period-cohort analysis on Kidney cancer mortality trend in China, 1992-2016 [J]. Chinese Journal of Epidemiology, 2021, 42(3):508-512.
[3] MA Shenghong, MENG Zhipeng, CHEN Rui, et al. The hippo pathway: biology and pathophysiology[J]. Annual Review of Biochemistry, 2019, 88(12): 577-604.
[4] LEE Y, FINCH-EDMONDSON M, COGNART H, et al. Common and unique transcription signatures of YAP and TAZ in gastric cancer cells[J]. Cancers(Basel), 2020, 12(12): 3667.
[5] ZHANG Shihao, ZHOU Dawang. Role of the transcriptional coactivators YAP/TAZ in liver cancer[J]. Current Opinion in Cell Biology, 2019, 61(10): 64-71.
[6] SANTORO R, ZANOTTO M, SIMIONATO F, et al. Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer[J]. Molecular Cancer Therapeutics, 2020, 19(1): 247-257.
[7] WANG Xiaojun, OU Hui, ZHOU Liangfen, et al. Long non-coding RNA LUCAT1 promotes the progression of clear cell renal cell carcinoma via the microRNA-375/ YAP1 axis[J]. Experimental and Therapeutic Medicine, 2021, 22(1): 754.
[8] CHEN Pingfeng, DUAN Youjun, LU Xinsheng, et al. RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation[J]. Cancer Immunology, Immunotherapy : CII, 2021, 70(11): 3261-3275.
[9] 郑振东 .NCCN肾癌指南 2015.V.3版更新解读 [J].浙江医学 , 2015, 37(5): 353, 356. ZHENG Zhendong. NCCN guidelines for renal cancer 2015 5. Interpretation of version 3 Update[J]. Zhejiang Medical Journal, 2015, 37(5):353, 356.
[10] DUNNICK N R. Renal cell carcinoma: staging and surveillance[J]. Abdominal Radiology (New York), 2016, 41(6): 1079-1085.
[11] DELAHUNT B, EBLE J N, EGEVAD L, et al. Grading of renal cell carcinoma[J]. Histopathology, 2019, 74(1): 4-17.
[12] CSCO肾癌专家委员会．中国肾癌诊治指南 [M]．北京：人民卫生出版社 , 2013：147-151． CSCO Expert Committee on Renal Cancer .Chinese guidelines for diagnosis and treatment of renal cell carcinoma[M]. Beijing: People’s Health Publishing House, 2013:147-151.
[13] 高级卫生专业技术资格考试指导用书委员会 ,中华医学会组织．病理学高级教程 [M]．北京：人民军医出版社 , 2015：189-201． Senior Health Professional Technical Qualification Examination Guidance Committee, Chinese Medical Association. Advanced course of pathology [M]. Beijing:People’s Military Medical Press, 2015:189-201.
[14] LJUNGBERG B, ALBIGES L, ABU-GHANEM Y A, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update[J]. European Urology, 2019, 75(5): 799-810.
[15] 张明威 , 陈阳 , 王静 , 等 .肾细胞癌患者癌组织和血清微囊泡 miR-378表达水平的临床应用价值研究 [J].现代检验医学杂志 , 2022, 37(2): 1-5, 11. ZHANG Mingwei, CHEN Yang, WANG Jing, et al. Clinical value of miR-378 expression levels in tumor tissue and serum extracellular vesicles for renal cell carcinoma patients and its function prediction[J]. Journal of Modern Laboratory Medicine, 2022, 37(2):1-5, 11.
[16] GRAY R E, HARRIS G T. Renal cell carcinoma: diagnosis and management[J]. American Family Physician, 2019, 99(3): 179-184.
[17] WHITE S M, MURAKAMI S, YI Chunling. The complex entanglement of Hippo-Yap/Taz signaling in tumor immunity[J]. Oncogene, 2019, 38(16): 2899-2909.
[18] YANG W H, LIN C C, WU Janli, et al. The hippo pathway effector YAP promotes ferroptosis via the E3 ligase SKP2[J]. Molecular Cancer Research, 2021, 19(6): 1005-1014.
[19] 徐明彬 , 赵雨桐 , 黎承杨 , 等．术前外周血淋巴细胞与单核细胞比值和清蛋白在肾透明细胞癌预后评估中的价值 [J].中国癌症杂志 , 2019, 29(11): 887-898. XU Mingbin, ZHAO Yutong, LI Chengyang, et al. Predictive value of lymphocyte-to-monocyte ratio and serum albumin in patients with clear cell renal cell carcinoma [J]. China Oncology, 2019, 29(11):887-898.
[20] 王强 , 王保军 , 李晓利 , 等．肾癌的临床、病理特征及预后 :单中心 4 167例资料分析 [J].解放军医学杂志 , 2019, 44(8): 666-670. WANG Qiang, WANG Baojun, LI Xiaoli, et al. Clinical, pathological features and prognosis of renal carcinoma: A single-center analysis of 4 167 cases [J]. Medical Journal of Chinese People’s Liberation Army, 2019, 44(8):666-670.
[21] 中国临床肿瘤学会指南工作委员会组织 .中国临床肿瘤学会 (CSCO)肾癌诊疗指南-2019[M].北京 : 人民卫生出版社 , 2019: 14-16． Guidelines Working Committee of Chinese Society of Clinical Oncology .Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of renal cancer 2019[M]. Beijing. People’s Health Publishing House, 2019:14-16.
[22] NGUYEN C D K, YI Chunling. YAP/TAZ signaling and resistance to cancer therapy[J]. Trends in Cancer, 2019, 5(5): 283-296.
[23] ZANCONATO F, CORDENONSI M, PICCOLO S. YAP and TAZ: a signalling hub of the tumour microenvironment [J]. Nat Rev Cancer, 2019, 19(8):454-464.
[24] 王晓琴 , 高慧 , 刘静静 , 等．索拉菲尼与舒尼替尼对转移性肾细胞癌患者的近远期疗效及预后影响因素分析 [J].中国肿瘤临床与康复 , 2019, 26(12): 1467-1470. WANG Xiaoqin, GAO Hui, LIU Jingjing, et al. Short-and long-term efficacy of sorafenib and sunitinib for metastatic renal cell carcinoma and the factors influencing the prognosis[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2019, 26(12):1467-1470.
[25] 邵彦翔 , 窦卫超 , 胡旭 , 等 .肾细胞癌不同病理组织亚型与预后的关系 [J].中华泌尿外科杂志 , 2021, 42(2): 89-96. SHAO Yanxiang, DOU Weichao, HU Xu, et al. Comparison of the prognosis of subgroup of renal cell carcinoma of different pathological types [J]. Chinese Journal of Urology, 2021, 42(2):89-96.
[26] SHAO Yanxiang, XIONG Sanchao, SUN Guangxi, et al. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma[J]. Cancer Medicine, 2020, 9(3): 959-970.
[27] 刘峰 , 蔡孟会 , 葛天宇 , 等．转移性肾癌患者的预后影响因素分析 [J]．生物技术 , 2020, 30(5): 495-503. LIU Feng, CAI Menghui, GE Tianyu, et al. Analysis of factors affecting the prognosis of patients with metastatic renal cell carcinoma [J]. Biotechnology, 2020, 30(5):495-503.

相似文献/References:

[1]钟双泽,陈尚金,林汉胜,等.基于TCGA 数据库生物信息学分析构建肾癌N6- 甲基腺苷相关LncRNA 配对模型及其预后预测价值研究[J].现代检验医学杂志,2024,39(02):68.[doi:10.3969/j.issn.1671-7414.2024.02.013]
　ZHONG Shuangze,CHEN Shangjin,LIN Hansheng,et al.Construction of N6-methyladenosine Related LncRNA Pairing Model for Renal Cell Carcinoma Based on Bioinformatics Analysis of TCGA Database and Its Prognostic Value Research[J].Journal of Modern Laboratory Medicine,2024,39(06):68.[doi:10.3969/j.issn.1671-7414.2024.02.013]

备注/Memo

备注/Memo:
基金项目：2020 年度安徽省自然科学基金项目(项目编号：2008085MH290)。
作者简介：高明珠(1988-)，女，硕士，主治医师，研究方向：泌尿系肿瘤，E-mail：gaomingzhu11@aliyun.com。
通讯作者：王进有(1985-)，男，博士，副主任医师，研究方向：泌尿系肿瘤，E-mail：jinyouwang@126.com。
更新日期/Last Update: 2022-11-15